BTT 1023

Drug Profile

BTT 1023

Alternative Names: Anti-VAP-1 monoclonal antibody fully human; BTT-1023; Fully human anti-VAP-1 monoclonal antibody; Fully human anti-vascular adhesion protein 1 monoclonal antibody; SI-3106

Latest Information Update: 30 Aug 2016

Price : $50

At a glance

  • Originator Biotie Therapies Corp.
  • Developer Biotie Therapies Corp.; Seikagaku Corporation
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action AOC3 protein inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary sclerosing cholangitis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Primary sclerosing cholangitis
  • No development reported Inflammation; Plaque psoriasis; Rheumatoid arthritis

Most Recent Events

  • 26 Aug 2016 BTT 1023 receives Orphan Drug status for Primary sclerosing cholangitis in USA
  • 28 Jul 2016 Biotie applies for Orphan Drug status in Primary sclerosing cholangitis in USA
  • 09 May 2016 No recent reports on development identified - Phase-I for Inflammation (In volunteers) in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top